USA - NYSEARCA:YCBD - US12482W4087 - Common Stock
The current stock price of YCBD is 0.8745 USD. In the past month the price decreased by -24.61%. In the past year, price decreased by -76.18%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 39.24 | 816.66B | ||
| JNJ | JOHNSON & JOHNSON | 18.2 | 454.86B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 18.56 | 255.48B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.83 | 239.64B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 12.81 | 219.77B | ||
| MRK | MERCK & CO. INC. | 9.87 | 214.76B | ||
| PFE | PFIZER INC | 7.27 | 140.15B | ||
| SNY | SANOFI-ADR | 11.52 | 123.27B | ||
| GSK | GSK PLC-SPON ADR | 7.73 | 94.25B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.02 | 93.77B | ||
| ZTS | ZOETIS INC | 23.17 | 63.86B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 48 | 42.45B |
cbdMD, Inc. engages in the business of operating cannabidiol brands such as Paw cannabidiol and cbdMD botanicals. The company is headquartered in Charlotte, North Carolina and currently employs 42 full-time employees. The company went IPO on 2017-11-17. The firm has a comprehensive line of United States produced, THC-free CBD products, including NSF Certified for Sport products, as well as its new Full Spectrum products. The firm's flagship brands include cbdMD and Paw CBD, as well as its functional mushroom brand ATRx Labs. Its cbdMD brand includes high-grade, premium CBD products including CBD tinctures, CBD gummies, CBD topicals, CBD capsules, CBD sleep aids and CBD drink products including its Herbal Oasis Social Tonic and an array of Farm Act compliant Delta 9 products. Its Paw CBD brand of pet products includes veterinarian-formulated products including tinctures, chews, topicals products in varying strengths, and its ATRx brand of natural functional mushroom support. Its cbdMD, Paw CBD and ATRx products are distributed through its e-commerce websites, third party e-commerce sites, select distributors and marketing partners as well as a variety of brick-and-mortar retailers.
CBDMD INC
8845 Red Oak Blvd
Charlotte NORTH CAROLINA 28217 US
CEO: Martin A. Sumichrast
Employees: 42
Phone: 17044453060
cbdMD, Inc. engages in the business of operating cannabidiol brands such as Paw cannabidiol and cbdMD botanicals. The company is headquartered in Charlotte, North Carolina and currently employs 42 full-time employees. The company went IPO on 2017-11-17. The firm has a comprehensive line of United States produced, THC-free CBD products, including NSF Certified for Sport products, as well as its new Full Spectrum products. The firm's flagship brands include cbdMD and Paw CBD, as well as its functional mushroom brand ATRx Labs. Its cbdMD brand includes high-grade, premium CBD products including CBD tinctures, CBD gummies, CBD topicals, CBD capsules, CBD sleep aids and CBD drink products including its Herbal Oasis Social Tonic and an array of Farm Act compliant Delta 9 products. Its Paw CBD brand of pet products includes veterinarian-formulated products including tinctures, chews, topicals products in varying strengths, and its ATRx brand of natural functional mushroom support. Its cbdMD, Paw CBD and ATRx products are distributed through its e-commerce websites, third party e-commerce sites, select distributors and marketing partners as well as a variety of brick-and-mortar retailers.
The current stock price of YCBD is 0.8745 USD. The price decreased by -0.62% in the last trading session.
YCBD does not pay a dividend.
YCBD has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
The Revenue of CBDMD INC (YCBD) is expected to decline by -2.84% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
CBDMD INC (YCBD) has a market capitalization of 7.79M USD. This makes YCBD a Nano Cap stock.
ChartMill assigns a technical rating of 2 / 10 to YCBD. When comparing the yearly performance of all stocks, YCBD is a bad performer in the overall market: 94.53% of all stocks are doing better.
ChartMill assigns a fundamental rating of 2 / 10 to YCBD. While YCBD seems to be doing ok healthwise, there are quite some concerns on its profitability.
Over the last trailing twelve months YCBD reported a non-GAAP Earnings per Share(EPS) of -6.03. The EPS increased by 71.77% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -49.02% | ||
| ROE | -79.38% | ||
| Debt/Equity | 0 |
7 analysts have analysed YCBD and the average price target is 2.04 USD. This implies a price increase of 133.28% is expected in the next year compared to the current price of 0.8745.
For the next year, analysts expect an EPS growth of 92.04% and a revenue growth -2.84% for YCBD